º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

Merck scraps £1bn London research centre and axes 127 jobs in fresh blow to º£½ÇÊÓÆµ

The US pharma giant is to lay off 127 staff alongside abandoning the construction project, which had been set to open in King's Cross in 2027. The firm warned the º£½ÇÊÓÆµ would lag behind the rest of Europe for spending on health research unless it made conditions more attractive to invest.

Merck warned on the º£½ÇÊÓÆµâ€™s attractiveness for investment(Image: PA)

Merck has withdrawn from a proposed £1bn London pharmaceutical research facility in the latest setback to the government's growth strategy.

The American pharmaceutical behemoth will make 127 employees redundant whilst scrapping the construction scheme, which was scheduled to launch in King's Cross during 2027, as reported by .

The company cautioned that Britain would fall behind the remainder of Europe in health research investment unless it enhanced conditions to attract capital.

"Unless a change is made to the operating environment, the undervaluation is corrected, and the investment is put back in the right places, more and more companies will be making these sorts of decisions," Merck said.

"Simply put, the º£½ÇÊÓÆµ is not internationally competitive."

Industry losing patience with Labour

The decision mirrors a comparable move by Cambridge-headquartered pharmaceutical company Astrazeneca earlier this year, after it abandoned a £450m scheme to expand its vaccine manufacturing capabilities in the º£½ÇÊÓÆµ.

Subsequently, Astrazeneca announced it would commit $50bn to manufacturing and R&D in the US, stating that the decision "underpins our belief in America's innovation in biopharmaceuticals."

The FTSE 100 member is also believed to have been weighing up relocating its primary listing from London to New York, a shift which would deliver another blow to the º£½ÇÊÓÆµ. Merck, known as MSD in the º£½ÇÊÓÆµ, first revealed plans for the new King's Cross facility in 2017 as part of a new º£½ÇÊÓÆµ headquarters, with construction set to begin in 2023.